SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SANGUINE CORP. (SGNC)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mr. Forthright who wrote (2479)7/2/1998 10:05:00 PM
From: dwlima  Read Replies (1) of 5402
 
i would imagine that there are cost of goods and sales costs that need to be assumed to arrive at a gross and net margin. and since after-tax net income is NOT the principal number used in cash-flow valuations- we will need to a net working capital analysis, depreciation analysis (they will need property, plant equipment to produce this product) and so on...to arrive to cash-flows.

i think your on the right track though and i will be glad to help you along in finding your value for SGNC. like i said though- it is all for nothing. this is like the valuation of any new, revolutionary product...its success for the most part depends on 80% of the abiility of management to sell their ideas to gain financing and 20% on the technical expertise to develop the product.

dwlima

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News